Thanks to its 2009 acquisition of biotech pioneer Genentech, Roche controls three of the world's ... Earnings in 2016 were only slightly above 2012 levels. And Roche's stock is 17% below its all-time high, reached in 2015. One key investor …
Shares of NewLink Genetics Corp. NLNK, +3.43% plunged 31% in premarket trade Thursday, putting them on track to …
SAN FRANCISCO, May 3— The wife of Genentech's chief executive officer is the focus of an insider trading investigation being conducted by the Securities and Exchange Commission, the company disclosed today. The investigation …
"Art" Levinson. The biotech company's experimental drug, Avastin, had failed a key trial in breast cancer in September, 2002, causing Genentech's stock to nose-dive 14%, to $27.50, in one day. Why, analysts wondered, would Levinson …
Genentech, Inc. (NYSE: DNA) today announced that Roche Holdings, Inc. intends to sell in an underwritten public …
Roche is offering $86.50. There are no other bidders. That's the price of Genentech stock. Side note: Here's an interesting story about Roche's lack of financing for the deal. Apparently, it's currently looking for a $27 billion bridge commitment …
As of today, it added, Genentech’s stock no longer will be listed on the New York Stock Exchange. Roche had owned about 56 percent of Genentech before launching a bid last year to buy the rest of the company. It said it now controls …
NEW YORK (CNNMoney.com) - Genentech's stock jumped more than 5 percent on Friday after the biotech said its earnings would surge by up to 50 percent in 2006. The biotech, based in South San Francisco, also said it expects to …